ZERIT XR
LOE ApproachingNDAORALCAPSULE, EXTENDED RELEASE
Approved
Dec 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZERIT XR is an extended-release oral capsule small-molecule drug approved by Bristol Myers Squibb in 2002. The specific indication and mechanism of action are not publicly detailed in available data, limiting clinical context. The extended-release formulation suggests chronic disease management with improved dosing convenience.
LOE Approaching
As LOE approaches, the brand team is likely consolidating and shifting focus to lifecycle extension strategies or transitioning portfolio responsibilities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ZERIT XR offers limited growth trajectory given LOE approaching status; roles focus on managing decline, defending market share, and supporting generic transition. Career development here is best suited for professionals seeking mature-product management experience or transition planning expertise.
Brand ManagerField Sales Representative
Worked on ZERIT XR at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.